Non-alcoholic steatohepatitis

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 11, 2004, Pages 1079-1085

  Jansen, Peter L M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adiponectin; Insulin resistance; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Obesity; Oxidative stress; Peroxisome proliferator activated receptor; Sterol regulatory element binding protein; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETAINE; BILE ACID; CHENODEOXYCHOLIC ACID; CHOLINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; URSODEOXYCHOLIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIET; DISEASE COURSE; ECHOGRAPHY; EXERCISE; FATTY LIVER; GLYCOGEN SYNTHESIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; FATTY LIVER; HEPATITIS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; WEIGHT LOSS;

EID: 8444242946     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200411000-00001     Document Type: Review

References (87)

1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98:960-967.
2. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134-140. In this case-control study patients with hepatocellular carcinoma (HCC) and cryptogenic cirrhosis more often were obese or had type 2 diabetes mellitus or hypertriglyceridaemia than age-matched and sex-matched cases with HCC and cirrhosis due to viral or alcoholic aetiology.
3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917-923.
4. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356-1362.
5. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300:1140-1142. Lean healthy elderly persons were more often insulin resistant and more often had increased fat accumulation in liver and muscle than young participants to this study. Elderly persons had a reduced mitochondrial oxidative and phosphorylation activity as measured by proton magnetic resonance spectroscopy.
6. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24:3-20.
7. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99:292-298.
8. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35:1485-1493. Survival of obese persons with cryptogenic cirrhosis was lower than that of age-matched and sex-matched patients with hepatitis C-related cirrhosis. In this French study hepatocellular carcinoma occurred with similar rates in both groups.
9. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38:420-427. In this Australian study survival of patients with NASH-related cirrhosis and HCV-related cirrhosis was similar. Hepatocellular carcinoma occurred more often in patients with HCV-related cirhosis.
10. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcohotic steatohepatitis. J Hepatol 2002; 37:154-160.
11. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
12. Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12:398-403.
13. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16:49-56.
14. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-1419.
15. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50:1844-1850.
16. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35:373-379. This study reports on a near universal relation between insulin resistance and NASH in both obese and lean patients. Insulin resistance is more frequent in NASH than in patients with HCV-cirrhosis of similar age and gender and a similar degree of fibrosis.
17. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35:367-372.
18. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39:1049-1055.
19. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17:873-881.
20. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:1117-1123.
21. Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002; 2:210-215.
22. Roberts EA. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep 2003; 5:253-259.
23. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-750.
24. Talwalkar JA. Motion - all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol 2002; 16:718-721.
25. Tarasow E, Siergiejczyk L, Panasiuk A, Kubas B, Dzienis W, Prokopowicz D, Walecki J. MR proton spectroscopy in liver examinations of healthy individuals in vivo. Med Sci Monit 2002; 8:MT36-MT40.
26. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bereich L, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5:281-285.
27. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125-1131.
28. Ntambi JM, Miyazaki M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res 2004; 43:91-104.
29. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nature Cell Biol 2004; 6:351-357. Hepatic insulin receptor substrate 2 (IRS-2) is decreased and sterol regulatory element binding protein-1 (SREBP-1) is increased in re-fed wild type mice. IRS-2 repression did not occur in SREBP-1 knock-out mice. Transcription studies in HepG2 cells showed that the IRS-2 promoter is activated by forkhead proteins through an insulin-response element. SREBPs suppress IRS-2 expression by interfering with the binding of these transactivators.
30. Kotzka J, Muller-Wieland D. Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin Ther Targets 2004; 8:141-149.
31. Uesugi T, Froh M, Arteel GE, Bradford BU, Wheeler MD, Gabele E, et al. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002; 168:2963-2969.
32. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001; 34:101-108.
33. Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003; 10:447-456.
34. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7:1034-1044.
35. Yahagi N, Shimano H, Matsuzaka T, Sekiya M, Najima Y, Okazaki S, et al. p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 2004; 279:20571-20575. p53 expression is increased in the hepatocyte nucleus of ob/ob mice and in SREBP-1 transgenic mice. Both SREBP-1 as well as p53 gene disruption ameliorated liver injury in ob/ob mice as indicated by a decrease of serum ALT levels.
36. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol, Gastrointest Liver Physiol 2002; 282:G193-G199.
37. Barrero MJ, Camarero N, Marrero PF, Haro D. Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through a partially conserved peroxisome proliferator-responsive element. Biochem J 2003; 369:721-729.
38. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol, Gastrointest Liver Physiol 2001; 281:G1135-G1139.
39. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, Thummel KE. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003; 38:428-435.
40. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001; 21:193-230.
41. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27:128-133.
42. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37:544-550.
43. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38:123-132. This study shows the central but complicated role of PPAR-á in hepatic steatohepatitis. Mice fed a methionine-choline deficient high fat diet readily develop hepatic steatosis with elevated serum ALT activity. Concomitant administration of a PPAR-α agonist ameliorated the steatosis and decreased the serum ALT activity. Hepatic triglyceride content was higher in PPAR-α knock-out mice than in wild type mice. The authors conclude that PPAR-α activation removes fatty acids as substrates for lipid peroxidation and thus prevents diet-induced steatohepatitis in mice.
44. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 2003; 4:487-492.
45. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52:2882-2887.
46. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
47. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277:50230-50236.
48. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48:206-211.
49. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38:413-419.
50. Yamada S, Iida T, Tabata T, Nomoto M, Kishikawa H, Kohno K, Eto S. Alcoholic fatty liver differentially induces a neutrophil chemokine and hepatic necrosis after ischemia-reperfusion in rat. Hepatology 2000; 32:278-288.
51. Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, Williams R. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993; 18:41-46.
52. Yamauchi T, Kamon J, Minokoshi Y, Ito V, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med 2002; 8:1288-1295. Evidence is presented for stimulation by adiponectin of glucose utilization and fatty acid oxidation. This occurs through activation and phosphorylation of 5′-AMP-activated protein kinase.
53. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423:762-769.
54. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125:1796-1807. Adiponectin knock-out mice show more extensive fibrosis and increased TGF-β activity upon administration of carbon tetrachloride than wild type mice. Administration of adenovirus producing adiponectin prevented the liver fibrosis.
55. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100.
56. Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004; 53:123-129.
57. Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol, Gastrointest Liver Physiol 2001; 281:G865-G869.
58. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002; 277:19353-19357.
59. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38:1529-1539. Polyunsaturated fatty acids when fed to ob/ob mice decreased the hepatic SREBP-1 expression and as a consequence reduced the activity of the lipogenic enzymes fatty acid synthase and stearoyl-CoA desaturase thereby decreasing the hepatic triglyceride content and serum ALT activity. Administration of polyunsaturated fatty acids improved insulin sensitivity.
60. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31:384.
61. Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D, Konikoff FM. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology 2003; 38:436-442.
62. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98:2485-2490.
63. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nature Med 2000; 6:998-1003.
64. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358:893-894.
65. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998; 129:38-41.
66. Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol 2001; 96:1631-1634.
67. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38:1008-1017. Thirty patients with biopsy-proven NASH received rosiglitazone 4 mg twice daily for 48 weeks. Liver histology improved, serum ALT levels decreased and insulin sensitivity increased in this open label uncontrolled study. Weight gain was noted in 67% of patients.
68. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39:188-196.
69. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122:1924-1940.
70. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, et al. Activation of peroxisome proliferator-activated receptor {delta} induces fatty acid {beta}-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003; 100:15924-15929.
71. Angelin B, Einarsson K, Hellstrom K, Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res 1978; 19:1017-1024.
72. Bateson MC, Maclean D, Evans JR, Bouchier IA. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br J Clin Pharmacol 1978; 5:249-254.
73. Carulli N, Ponz de Leon M, Podda M, Zuin M, Strata A, Frigerio G, Digrisolo A. Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J Clin Pharmacol 1981; 21:436-442.
74. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113:1408-1418. Cholic acid administration decreased hepatic and serum triglyceride levels in a mouse model of hypertriglyceridaemia. The molecular mechanism of this effect lies in the activation of the farnesoid X receptor (FXR) by the bile acid with induction of the small heterodimer partner SHP that interferes with the activation of SREBP-1c by the liver X receptor, LXR. Thus FXR activation may prove an interesting target for therapies aimed at correcting hypertriglyceridaemia.
75. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99:1408-1413.
76. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27:103-107.
77. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003; 98:926-930.
78. Booth AM, Caldwell SH, Iezzoni JC. Troglitazone-associated hepatic failure. Am J Gastroenterol 2000; 95:557-558.
79. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734-738.
80. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5:18-25.
81. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19:221-229.
82. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003; 38:681-687.
83. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37:343-350.
84. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23:1464-1467.
85. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96:2711-2717.
86. Egawa T, Toda K, Nemoto Y, Ono M, Akisaw N, Saibara T, et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids 2003; 38:519-523.
87. Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, Naserimoghadam S. Probucol in the treatment of nonalcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38:414-418.